UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report: December 21, 2006

Date of earliest event reported: December 18, 2006

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other Jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

235 East 42nd Street

New York, New York

(Address of principal executive offices)

10017

(Zip Code)

Registrant's telephone number, including area code:

(212) 573-2323

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

[ ] Written communication pursuant to Rule 425 under the Securities Act (17

CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17

CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Item 5.02

Departure of Directors or Certain Officers; Election

of Directors; Appointment of Certain Officers; Compensatory Arrangements

of Certain Officers.

Henry A. McKinnell served as an executive of Pfizer Inc.

( Pfizer ) for 36 years, beginning in 1971. He became Chief

Executive Officer in 2001, and subsequently entered into an employment

agreement with Pfizer dated as of January 1, 2001 (the Employment

Agreement ). Among other provisions pertaining to Dr. McKinnell s

compensation and conditions of service, the Employment Agreement specifies

the parties' rights and obligations upon the termination of his employment

for various reasons.

On July 28, 2006, Pfizer announced that Jeffrey B. Kindler would succeed

Dr. McKinnell as Chief Executive Officer of Pfizer effective July 31,

2006 ( Resignation Date ). At that time, it was agreed that

Dr. McKinnell would continue to serve as the Chairman of the Board of

Directors of Pfizer (the Board ) and as a Pfizer employee

through February 28, 2007 ( Termination Date ), so there would

be an orderly transition of his responsibilities. On December 18, 2006,

Dr. McKinnell resigned from his position as Chairman of the Board.

The Board s replacement of Dr. McKinnell as Chief Executive Officer

with Mr. Kindler contractually obligated Pfizer under the Employment Agreement

to provide Dr. McKinnell with certain severance payments and benefits.

In addition, Pfizer is obligated to provide Dr. McKinnell with pension

benefits under Pfizer s retirement annuity plan and supplemental

retirement annuity plan as well as distributions with respect to prior

compensation that Dr. McKinnell elected to defer under Pfizer s

supplemental savings plan and other deferred compensation plans for personal

tax-planning purposes. A major payment obligation to Dr. McKinnell is

for pension benefits with an estimated lump sum value of approximately

$82 million, which was previously disclosed in Pfizer s 2006 Definitive

Proxy Statement filed on March 16, 2006. Another major obligation is the

payment of approximately $78 million of nonqualified deferred compensation

owed to Dr. McKinnell, which will be paid in accordance with his payment

elections under such plans. This amount includes approximately $67 million

of Dr. McKinnell s own money from prior compensation that he had

earned and voluntarily elected to defer with Pfizer. Pfizer has had the

use of these funds in the business during the deferral period and has

credited Dr. McKinnell with investment returns applicable to each deferral.

No above-market or preferential earnings have been credited. This amount

also includes matching contributions to which he, like other Pfizer employees

participating in the plan, was entitled to receive under Pfizer s

supplemental savings plan.

On December 18, 2006, Pfizer entered into an agreement with Dr. McKinnell

which details the terms of his departure from Pfizer (the Agreement ).

Under the Agreement, Dr. McKinnell has agreed to step down from his position

on the Board and to retire from employment and all other positions with

Pfizer then held by him on the Termination Date. Dr. McKinnell will continue

to be paid his regular base salary, and continue to be eligible to participate

in Pfizer s employee benefit plans and programs and to receive certain

protective services from Pfizer, through the Termination Date.

The amounts and benefits payable to Dr. McKinnell as a result of his

departure as Chief Executive Officer do not exceed or are less than the

amounts and benefits that Pfizer would have been obligated to pay under

the Employment Agreement had his employment terminated without cause on

the Resignation Date. Under the Agreement, Dr. McKinnell will receive

the following payments and benefits as a result of his departure: (i)

severance of $11,941,000, payable in a single lump sum on March 15, 2007,

which equals two times the sum of his base salary and 2005 bonus, (ii)

payment on March 15, 2007 of a pro-rata bonus for 2006 in the amount of

$2,158,300, which equals his 2005 bonus prorated through the Resignation

Date, (iii) payment on March 15, 2007 of $305,644 for accrued but unused

vacation time through the Termination Date, (iv) the benefits, or payment

of $576,573 on March 15, 2007 for the nominal value of the benefits, Dr.

McKinnell would receive under Pfizer s savings plan, supplemental

savings plan and medical, dental, life insurance, long-term disability

and financial counseling programs if his employment with Pfizer had continued

for two additional years, (v) full vesting of all unvested restricted

stock and restricted stock unit awards, with a value of $5,783,156, based

on the closing price of Pfizer common stock on December 13, 2006, and

full vesting of all unvested stock options with continued exercisability

of all stock options through the expiration dates of such options, each

in accordance with their original terms and conditions (including Dr.

McKinnell s compliance with restrictions on competition, disclosure

or misuse of confidential information and engaging in certain activities

harmful to Pfizer), and (vi) continued medical and dental coverage under

Pfizer s retiree plans for himself and his partner, subject to the

terms of such plans. In addition, under the Agreement, Dr. McKinnell s

outstanding performance-contingent share and performance share awards

will be settled in accordance with the original terms and conditions of

such awards (including Dr. McKinnell s compliance with restrictions

on competition, disclosure or misuse of confidential information and engaging

in certain activities harmful to Pfizer) by the delivery of a number of

shares of common stock calculated based on Pfizer s actual performance

relative to the pharmaceutical peer group during each applicable performance

period, assuming for this purpose that Dr. McKinnell remained employed

by Pfizer through the date of payment, except that the amount of the award

for the performance periods that commenced on January 1, 2003 and January

1, 2005 and with respect to 198,000 target shares subject to the award

for the performance period that commenced on January 1, 2004 will be prorated

for the number of days during the applicable performance period Dr. McKinnell

was employed by Pfizer. If target level performance is achieved with respect

these outstanding awards, Dr. McKinnell would receive in settlement of

such awards 719,533 shares of Pfizer common stock with an aggregate value

of $18,268,943, based on the closing price of Pfizer common stock on December

13, 2006. Additional information about the terms and conditions of Dr.

McKinnell s performance-contingent share and performance share awards

is contained in Pfizer s Definitive Proxy Statement filed on March

16, 2006 and Pfizer s Form 8-K filed on February 24, 2006. Dr. McKinnell

did not and will not receive any additional grants of share or equity-based

awards after the Resignation Date.

If any payment or benefit required under the Agreement cannot be provided

or made at the specified time without incurring sanctions under Section

409A of the Internal Revenue Code, then such benefit or payment shall

be provided in full at the earliest time when such sanctions will not

be imposed. If the severance, pro-rata bonus or accrued vacation payments

described above are delayed to avoid sanctions under Section 409A, Pfizer

has agreed to pay interest at a market rate on these amounts during such

delay.

In the Agreement, Dr. McKinnell has agreed to be bound by customary confidentiality

and non-competition covenants following the Terminate Date, to provide

reasonable litigation assistance to Pfizer and its counsel following the

Terminate Date and to execute a release of claims in favor of Pfizer.

Dr. McKinnell s and Pfizer s rights and obligations under

the Employment Agreement (other than Dr. McKinnell s right to indemnification,

which survives) and the Change in Control Severance Agreement between

Pfizer and Dr. McKinnell, as amended, have been terminated as a result

of the execution of the Agreement.

Nonqualified Deferred Compensation

Dr. McKinnell will receive approximately $78 million of nonqualified

deferred compensation in accordance with Pfizer s supplemental savings

and other deferred compensation plans (excluding the supplemental retirement

annuity plan), which includes approximately $67 million of his own money

from prior compensation he had earned and voluntarily elected to defer.

Amounts deferred at the election of Dr. McKinnell were previously disclosed

in the Summary Compensation Table contained in the Proxy Statement for

the fiscal year in which earned in accordance with applicable SEC disclosure

requirements then in effect.

Set forth below is certain additional information about Dr. McKinnell s

nonqualified deferred compensation under Pfizer s supplemental savings

and other deferred compensation plans, including Pfizer s contributions,

aggregate earnings and the balance of Dr. McKinnell s account under

such plans on December 13, 2006.

Nonqualified Deferred Compensation

Program

Dr. McKinnell s Contributions

Pfizer s

Contributions

Aggregate

Earnings

Balance on

December 13, 2006

Supplemental Savings (401(k) Type) Plan(1)

$10,770,489

$2,508,029

$13,278,518

Deferred Performance-Contingent Shares (2)

$37,599,112

$4,169,977

$41,769,089

Deferred Bonuses (3)

$18,788,495

$4,073,839

$22,862,334

Totals

$67,158,096

$2,508,029

$8,243,816

$77,909,941

(1) The amounts shown reflect net contributions

and return on those contributions on December 13, 2006.

(2) Dr. McKinnell voluntarily elected to defer receipt of 1,480,863 shares

of Pfizer common stock and received 164,237 shares (the value of which

is shown in the Aggregate Earnings column) as reinvested

dividends on the deferred shares. The values shown are based on the closing

price of Pfizer common stock on December 13, 2006 ($25.39).

(3) Dr. McKinnell voluntarily elected to defer receipt of $18,788,495

of bonus amounts and has received $4,073,839 as investment income on those

deferrals. Dr. McKinnell has deferred all or a portion of nine bonus awards.

Over that period, he has earned 120% of the Federal long-term rate on

those deferrals, which averaged an annual return of 5.7%.

Pension Benefits

Dr. McKinnell is entitled to receive pension benefits under Pfizer s

retirement annuity plan and supplemental retirement annuity plan as previously

disclosed in Pfizer s Definitive Proxy Statement filed on March

16, 2006. Set forth below are the number of years of plan service, his

estimated annual pension payable on February 28, 2007, if selected, and

the estimated lump sum value of his annual pension on February 28, 2007

under these plans.

Estimated Pension Benefits

Number of Years of Plan Service

Annual Pension Payable on February 28,

2007

Lump Sum Value of Annual Pension (1)

Retirement Annuity Plan and Supplemental Retirement Annuity Plan

35

$6,646,142

$82,305,823

(1) The lump sum amount was estimated based on the current interest rate of

4.69%, which is the most recent published rate. The actual amount will be determined

based on the interest rate effective for retirements on February 28, 2007.

Additional information about the retirement annuity plan and supplemental retirement

annuity plan is contained in Pfizer s Definitive Proxy Statement filed

on March 16, 2006.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit 10

Agreement between Pfizer Inc. and Henry A. McKinnell dated December 18,

2006.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Foran

Margaret M. Foran

Title: Senior Vice President-Corporate

Governance, Associate General Counsel and Corporate Secretary

Dated: December 21, 2006

EXHIBIT INDEX

Exhibit No.

Description

10

Agreement between Pfizer Inc. and Henry A. McKinnell dated December

18, 2006.